Narcolepsy With Cataplexy Narcolepsy Type 1 clinical trials

Explore recruiting narcolepsy with cataplexy narcolepsy type 1 clinical trials.

Recruiting narcolepsy with cataplexy narcolepsy type 1 studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Narcolepsy With Cataplexy Narcolepsy Type 1 trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Long-term Extension Trial to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions.

Norway, Finland, Germany, Italy, Spain, France +5 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)

Norway, Spain, Germany, Netherlands, France, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Open-label single dose trial to evaluate pharmacokinetics, safety, and acceptability/palatability of oveporexton in children from 6 years to less than 18 years of age with narcolepsy type 1 (NT1)

Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)

Denmark, Finland, France, Austria, Sweden, Czechia +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)

Spain, Italy, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Narcolepsy With Cataplexy Narcolepsy Type 1 trials by city

Narcolepsy With Cataplexy Narcolepsy Type 1 in Toronto Narcolepsy With Cataplexy Narcolepsy Type 1 in Vancouver Narcolepsy With Cataplexy Narcolepsy Type 1 in Montreal Narcolepsy With Cataplexy Narcolepsy Type 1 in Calgary Narcolepsy With Cataplexy Narcolepsy Type 1 in Edmonton Narcolepsy With Cataplexy Narcolepsy Type 1 in Ottawa Narcolepsy With Cataplexy Narcolepsy Type 1 in Winnipeg Narcolepsy With Cataplexy Narcolepsy Type 1 in Quebec City Narcolepsy With Cataplexy Narcolepsy Type 1 in Hamilton Narcolepsy With Cataplexy Narcolepsy Type 1 in Kitchener Narcolepsy With Cataplexy Narcolepsy Type 1 in London Narcolepsy With Cataplexy Narcolepsy Type 1 in Halifax Narcolepsy With Cataplexy Narcolepsy Type 1 in New York Narcolepsy With Cataplexy Narcolepsy Type 1 in Los Angeles Narcolepsy With Cataplexy Narcolepsy Type 1 in Chicago Narcolepsy With Cataplexy Narcolepsy Type 1 in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease